CLEOPATRA
2012
Clinical Evaluation of Pertuzumab and Trastuzumab
In 808 patients with HER2-positive metastatic breast cancer, first line, pertuzumab + trastuzumab + docetaxel improved progression-free and overall survival compared with placebo + trastuzumab + docetaxel.
Result
Efficacy: Independent-review PFS; final OSHR 0.62
Below 1 favours pertuzumab + trastuzumab + docetaxel, above 1 favours placebo + trastuzumab + docetaxel.
Event rates Pertuzumab + trastuzumab + docetaxel 18.5 vs placebo + trastuzumab + docetaxel 12.4 months
Also reported: Final OS 56.5 vs 40.8 months (HR 0.68).
- Subtopic
- HER2+ metastatic
- Design
- Double-blind RCT
- Relevance
- Practice-defining: a trial the field needs to know.
- Source
- Baselga J, et al. N Engl J Med. 2012;366(2):109-119; Swain SM, et al. N Engl J Med. 2015;372(8):724-734.doi 10.1056/NEJMoa1113216
Discussion & critique
Established dual HER2 blockade plus taxane as first-line standard in HER2+ metastatic breast cancer. Later displaced by trastuzumab deruxtecan in the second line (DESTINY-Breast03).